Skip to content
Home/Companies/Biotech/ReViral

ReViral

Biotech·UK·Exited 2022·Held 7yr
Entry
2015
Hold
7yr
Exit
2022

Who owns ReViral?

ReViral was owned by Andera Partners through BioDiscovery 4 (2013 vintage) from 2015 to 2022, exited via Trade Sale.

Buyer identity available on Pro.

Hand-verified · updated 2026-04-21

Andera Partners
Investor
Andera Partners
BioDiscovery 4 · 2013 · VC

Key facts

HQUnited Kingdom
SectorBiotech
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2022

More from BioDiscovery 4

Other portfolio companies in the same fund.

Inotrem
Active
BiotechFrance
MedDay Pharmaceuticals
Exited 2021
BiotechFrance· 2016
Verona Pharma
Verona Pharma
Exited 2017
BiotechUK· 2016
Autonomic Technologies
Exited 2020
MedTechUS· 2015
to
Gamamabs
Active
BiotechFrance· 2015
Sanifit
Exited 2021
BiotechSpain· 2015
to

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track ReViral

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy ReViral?

5 strategic and 115financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on ReViral.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue